The review, led by Seung-Jae Lee of the Korea Research Institute of Bioscience and Biotechnology, synthesizes decades of research into the biochemical composition of deer antler velvet, commonly abbreviated DAV. The tissue is a biochemical treasure chest: it contains abundant type I and type II collagen, a broad spectrum of bioactive peptides, and an impressive array of growth factors including insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), and several fibroblast growth factors. Alongside these sit glycosaminoglycans such as chondroitin sulfate and hyaluronic acid, essential and non-essential amino acids, minerals including calcium, phosphorus, magnesium, zinc, and iron, phospholipids, gangliosides, polysaccharides, nucleotides, and sialic acid. Each of these compound classes has documented biological activity in laboratory settings, which explains why DAV has attracted attention for applications ranging from joint health to neuroprotection.

The mechanistic story emerging from preclinical research is coherent, at least on paper. Growth factors found in DAV are known to engage canonical signaling cascades such as PI3K/Akt, MAPK/ERK, and JAK/STAT, pathways that govern cell proliferation, extracellular matrix synthesis, and tissue remodeling. In cell culture and animal models, DAV-derived fractions have been shown to stimulate osteoblast proliferation, promote chondrogenesis, accelerate wound closure, and support angiogenesis. Meanwhile, DAV peptides and polysaccharides appear to modulate redox balance by upregulating antioxidant enzymes like superoxide dismutase, catalase, and glutathione peroxidase, and to suppress inflammation through inhibition of the NF-κB pathway and modulation of MAPK signaling, reducing pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β while boosting the anti-inflammatory mediator IL-10. Gangliosides and phospholipids in the tissue have been linked to neuronal survival and synaptic plasticity, and rodent studies report improvements in learning and memory as well as protection against chemically induced neuronal damage.

But here is where the review delivers its most sobering message: biological plausibility is not clinical proof. The overwhelming majority of the evidence for DAV’s celebrated effects comes from in vitro experiments and animal models, with comparatively few well-controlled human trials. One of the few clinical studies examining physical performance, conducted with just 38 participants, produced outcomes that were not entirely consistent, and its small sample size limits statistical power and generalizability. Systematic reviews of randomized controlled studies of deer and elk velvet antler supplements have similarly found the human evidence base thin and heterogeneous. For conditions such as osteoporosis, cartilage degeneration, neurodegenerative disease, or chronic inflammation, no large-scale randomized controlled trials with clinically meaningful endpoints currently exist.

A deeper problem lurks beneath the evidence gap: the question of bioavailability. The star molecules of DAV, particularly IGF-1 and other peptide growth factors, are proteins, and proteins face a hostile journey through the human gastrointestinal tract, where digestive enzymes typically cleave them into fragments long before they could reach systemic circulation intact. The review emphasizes that the extent to which intact growth factors survive digestion and achieve physiologically relevant concentrations in the bloodstream remains fundamentally uncertain. This means that some observed biological effects may actually reflect smaller peptide fragments or indirect signaling modulation rather than direct systemic growth factor activity. Encapsulation, protective co-formulation, and controlled-release delivery systems are being explored to improve stability and absorption, but comprehensive pharmacokinetic data on DAV-derived growth factors in humans remain scarce.

Compounding the bioavailability problem is the issue of standardization. Deer antler velvet is not a single, uniform substance. Its composition varies with species, the age of the animal, the stage of antler growth at harvest, diet, seasonal factors, and processing methods. Hot water extraction, the most common traditional approach, effectively solubilizes proteins, peptides, and polysaccharides but can partially denature heat-sensitive growth factors. Ethanol extraction enriches lipid-soluble compounds but may reduce overall protein content. Modern techniques such as enzymatic hydrolysis, ultrasonic-assisted extraction, and supercritical CO₂ extraction offer improved yields and selectivity, with enzymatically hydrolyzed preparations showing higher immunomodulatory and osteogenic activity in some studies. Yet even with these advances, batch-to-batch reproducibility remains elusive, and internationally harmonized quality standards for DAV do not yet exist. Analytical tools including high-performance liquid chromatography, ELISA, and mass spectrometry are available for compositional profiling, but no universally accepted marker compounds have been established.

Safety data, while generally reassuring, carry their own caveats. Toxicological assessments in rodents report low acute and subchronic toxicity, with minimal adverse effects on liver and kidney function, hematological parameters, and behavior even at relatively high doses. However, long-term studies covering reproductive toxicity, carcinogenicity, and large-scale human safety are limited. The presence of growth-promoting molecules raises theoretical endocrine and oncogenic concerns, even though conventional DAV supplementation has not been conclusively associated with such adverse outcomes in humans. Allergenicity is biologically plausible given the tissue’s protein content, though documented severe allergic responses appear uncommon. The review also notes that growth-associated factors have attracted attention in athletic contexts regarding anti-doping compliance, although current evidence does not clearly demonstrate supraphysiological systemic effects from oral consumption.

The regulatory landscape is equally fragmented. In China and Korea, DAV is embedded within traditional medicinal systems and functional product frameworks, while in the United States and the European Union it is typically classified as a dietary supplement or natural health product subject to good manufacturing practices and restricted health claims. This patchwork of classifications, combined with compositional variability, creates a regulatory bottleneck: without quantified, reproducible marker compounds such as defined peptide fractions or measured IGF-1 levels, dose standardization and cross-border market integration remain difficult. Ethical considerations, including sustainable harvesting practices and animal welfare, are also increasingly shaping consumer acceptance and regulatory review.

What would it take for deer antler velvet to move from traditional remedy and speculative supplement to evidence-based therapeutic or functional ingredient? The review lays out a clear roadmap. First, researchers must establish defined compositional markers or fingerprints that correlate with biological activity, supported by validated analytical methods and bioassay-guided standardization. Second, rigorous pharmacokinetic and bioavailability studies are needed to determine which components, if any, reach systemic circulation in active form and at what doses. Third, well-powered randomized controlled trials evaluating clinically meaningful endpoints, rather than surrogate biomarkers, must be conducted with standardized formulations. Fourth, regulatory frameworks need harmonization grounded in reproducible quality control and transparent labeling. Technological innovations in extraction, stabilization, and delivery may help, but the authors caution that these must be accompanied by rigorous comparative evaluation rather than assumed improvements.

The broader lesson of the DAV story extends beyond a single ingredient. It illustrates a pattern familiar from many traditional natural products: a rich biochemical composition and compelling mechanistic plausibility that outpace the clinical evidence needed to justify health claims. Deer antler velvet genuinely contains molecules that regulate growth, redox balance, immune signaling, and tissue remodeling, and its intrinsic regenerative biology remains a fascinating model for studying angiogenesis, mineralization, and stem cell dynamics. But as the review’s authors conclude, the future of DAV in biomedical and nutraceutical applications will depend not on expanding the list of proposed benefits, but on deepening the validation behind each one. Until standardized compositions, pharmacokinetic clarity, and robust human trials arrive, consumers and clinicians alike should view this ancient remedy with informed, measured skepticism, appreciating its biological promise while recognizing how much rigorous science remains to be done.

Subject of Research: Bioactive composition, mechanisms, and translational challenges of deer antler velvet for biomedical and nutraceutical applications

Article Title: Deer antler velvet as a multifunctional natural resource for biomedical and nutraceutical applications

Article References: Lee, S.-J., Bak, S. G., Cheon, Y. J., Chandimali, N., & Bae, J. (2026). Deer antler velvet as a multifunctional natural resource for biomedical and nutraceutical applications. Food Science of Animal Resources, 46(1), Article 54. https://doi.org/10.1007/s44463-026-00070-z

Image Credits: AI Generated

DOI: 10.1007/s44463-026-00070-z

Keywords: deer antler velvet, IGF-1, growth factors, nutraceuticals, collagen, bioavailability, standardization, regenerative medicine, immunomodulation, antioxidant, functional foods, clinical trials